MwanzoASRT • NASDAQ
add
Assertio Holdings Inc
Bei iliyotangulia
$ 0.84
Bei za siku
$ 0.80 - $ 0.84
Bei za mwaka
$ 0.74 - $ 1.80
Thamani ya kampuni katika soko
76.05M USD
Wastani wa hisa zilizouzwa
elfu 809.48
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 29.20M | -18.03% |
Matumizi ya uendeshaji wa biashara | 24.40M | -18.13% |
Mapato halisi | -2.92M | 98.96% |
Kiwango cha faida halisi | -10.00 | 98.73% |
Mapato kwa kila hisa | 0.03 | 200.00% |
EBITDA | 3.96M | -56.54% |
Asilimia ya kodi ya mapato | -1.53% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 88.58M | 15.21% |
Jumla ya mali | 276.00M | -27.37% |
Jumla ya dhima | 145.48M | -22.27% |
Jumla ya hisa | 130.52M | — |
hisa zilizosalia | 95.48M | — |
Uwiano wa bei na thamani | 0.61 | — |
Faida inayotokana na mali | -2.47% | — |
Faida inayotokana mtaji | -4.00% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -2.92M | 98.96% |
Pesa kutokana na shughuli | elfu -35.00 | -101.36% |
Pesa kutokana na uwekezaji | -6.71M | -261.90% |
Pesa kutokana na ufadhili | elfu -10.00 | 0.00% |
Mabadiliko halisi ya pesa taslimu | -6.75M | -200.61% |
Mtiririko huru wa pesa | elfu 900.88 | 99.64% |
Kuhusu
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration. On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1995
Makao Makuu
Tovuti
Wafanyakazi
53
